AMENDMENT No. 3 to the NON-EXCLUSIVE LICENSE AGREEMENT Dated 6 February 2012 Between LONZA SALES AG and FIVE PRIME THERAPEUTICS, INC. and BIOWA, INC.
Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
CONFIDENTIAL
AMENDMENT No. 3
NON-EXCLUSIVE LICENSE AGREEMENT
and
BIOWA, INC.
CONFIDENTIAL
THIS AMENDMENT NO. 3 (this “Amendment No. 3”) is made the 17th day of July, 2019 (the “Amendment No. 3 Effective Date”)
BETWEEN
BIOWA, INC., a Delaware corporation, with a principal place of business at 000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, XX 00000, XXX (“BioWa”),
AND
LONZA SALES AG, a limited company incorporated and registered in Switzerland whose registered office is at Xxxxxxxxxxxxxxxxxxxxxx 00, XX-0000, Xxxxx, Xxxxxxxxxxx, (“Lonza" and together with BioWa, the “Licensor”)
FIVE PRIME THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 000 Xxxxxx Xxxxx Xxxxxxxxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000, XXX (“Licensee”).
|
A. |
Licensor and Licensee entered into a Non-Exclusive License Agreement dated 6 February 2012, as amended (hereinafter referred to as the “Agreement”) under which (inter alia) Lonza provided the materials set forth in Section 3.1 of the Agreement to Licensee for the purposes of the Commercial License (as defined in the Agreement); and |
CONFIDENTIAL
|
C. |
In connection with the [***] License, Licensee has granted to [***] the [***] Sublicense (as more fully defined in the new clause 2.2.4(a) contained in clause 2 hereof) in and to certain rights licensed to Licensee under the Agreement and is seeking prior consent from Licensor to transfer Transfected Cells and certain Licensor Know-How to [***] in connection therewith in relation to which a Material Transfer Agreement (as attached as Exhibit A to this Amendment No. 3) has been entered into; and |
NOW THEREFORE in consideration of the promises and covenants contained herein and other good and valuable consideration, the sufficiency of which is acknowledged, and intending to be legally bound it is hereby agreed by and between the parties to amend the Agreement as follows:
““[***]” means [***] with a principal place of business at [***] and/or its Affiliate located at: (i) [***](ii) [***] or (iii) [***].”
|
2. |
A new clause 2.2.4 shall be inserted into the Agreement as follows: |
“2.2.4(a)Subject to the terms and conditions of this Agreement, including Section 2.2, and in accordance with Section 2.2.2, Licensor hereby gives consent to the Licensee to sublicense to [***] the rights
CONFIDENTIAL
granted to Licensee under Section 2.1 in relation only to the Transfected Cells and Licensor Know-How granted to Licensee under Clause 2.1 and to transfer the Transfected Cells and Licensor Know-How to the extent required for the sole purpose of (i) [***] to the extent necessary for [***] (and [***]; (ii) [***] (and [***]); and (iii) [***] (and [***]), in each case (i), (ii) and (iii) in [***] only and on behalf of Licensee (the “[***] Sublicense”). For clarity, Licensee is not permitted to sublicense or transfer to [***] (or any third party) any other part of the Licensor IP, GS System, Potelligent Technology, the Potelligent CHOK1SV, and/or any other IP of Licensor.
“(b)Licensee confirms that on no occasion will [***] be permitted to transfer or sublicense the Transfected Cells, the Licensor Know-How and/or any other part of the Licensed Technology related thereto to any third party, and Licensee shall ensure that [***] shall not transfer or sublicense the Transfected Cells, the Licensor Know-How or any other part of the Licensed Technology related thereto to any third party.
“(c)Licensee shall grant the [***] Sublicense to [***] expressly subject to the terms of this Agreement, and Licensee shall be responsible for ensuring [***]’s strict adherence to the applicable terms and conditions of this Agreement and the [***] Sublicense. Any act or omission of [***], and/or any breach of this Agreement or the [***] Sublicense by [***], and/or any misuse by [***] of the Transfected Cells and/or Licensor Know-How by [***] shall be the responsibility of Licensee. In accordance with Section 2.2.2 of this Agreement, Licensee, [***], BioWa and Lonza have entered into the Material Transfer Agreement attached as Exhibit A to Amendment No. 3 to this Agreement.”
|
3. |
Save as herein provided, all other terms and conditions of the Agreement shall remain in full force and effect. |
CONFIDENTIAL
IN WITNESS WHEREOF, the parties have caused this Amendment No. 3 to be executed by their respective representatives thereunto duly authorised as of the Amendment No. 3 Effective Date.
Signed for and on behalf of.../s/ Bart van Aarnhem.................
TITLE Associate General Counsel
|
Signed for and on behalf of |
.../s/ Xxxxxx Xxxxxx........................ |
LONZA SALES AG
|
…Xx. Xxxxxx Xxxxxx....................... |
TITLE Assoc. General Counsel
Signed for and on behalf of
|
BIOWA, INC. |
.../s/ Xxxxxxx Xxxxxx..................... |
|
Xxxxxxx Xxxxxx |
TITLE: President and CEO
FIVE PRIME THERAPEUTICS, INC. …Xxxxx X. Xxxx, Ph.D..................
TITLE VP Bus Dev & Alliance Management
CONFIDENTIAL
